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Is More Better or Worse?*Duck-chul Lee, PHD,y Carl J. Lavie, MD,z Rajesh Vedanthan, MD, MPHxA lthough it is well known that regular exerciseand physical activity (PA) have health bene-ﬁts, there is still an unanswered question:
“Is it possible to have too much of a good thing?” In
particular, is high-intensity PA, such as running, a
healthful activity? The dose-response relationship
between running and mortality is still subject to
debate and controversy.SEE PAGE 411In this issue of the Journal, Schnohr et al. (1) report
3 major ﬁndings on jogging and all-cause mortality in
1,098 joggers and 3,950 nonjoggers from the Copen-
hagen City Heart Study. First, jogging even <1 h per
week or 1 time per week is associated with signiﬁcant
mortality risk reduction compared with sedentary
nonjoggers. Second, 1 to 2.4 h of jogging per week,
with a frequency of 2 to 3 times per week, at a slow or
average pace is most favorable as an optimal jogging
time, frequency, and speed for reducing mortality.
Third, higher jogging times ($2.5 h per week), higher
frequencies (>3 times per week), and faster paces are
not associated with better survival compared with
sedentary nonjoggers, suggesting a U-shaped*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.association between jogging and mortality as well
as loss of beneﬁts with higher doses of jogging.
Considering the current consensus of a linear dose-
response relationship between total PA and health,
indicating “the more the PA, the better for health and
longevity,” these ﬁndings are intriguing. The good
news is that the mortality beneﬁts of light jogging
will encourage more people to jog for health beneﬁts
as a “practical, achievable, and sustainable” goal, as
the authors have stated.
However, there are several important study limi-
tations that should be considered in the interpreta-
tion of these interesting results. First, all analyses
on the association between jogging and mortality
included only 413 sedentary nonjoggers and excluded
3,537 active nonjoggers who are active in other types
of PA. Considering other PA (sedentary vs. active)
and jogging, we can think of 4 categories of overall
PA: 1) sedentary nonjoggers, 2) active nonjoggers, 3)
sedentary joggers, and 4) active joggers. Comparing
mortality risk in joggers (both sedentary and active)
with mortality risk in the least active, sedentary
nonjoggers without active nonjoggers in the relative
risk analyses likely contributed to more signiﬁcant
mortality beneﬁts in joggers. In addition, sedentary
nonjoggers were more obese, were nearly 20 years
older, and had an approximately 5 to 6 times higher
prevalence of hypertension and diabetes mellitus
compared with joggers in this study, which could
increase the risk of mortality irrespective of jogging
status. Although the authors appropriately adjusted
for age and diabetes mellitus in their analyses, sta-
tistical adjustment would not completely eliminate
the confounding bias by these large differences,
potentially leading to overestimation of the mortality
beneﬁts of jogging.
Second, Schnohr et al. (1) used a practical but
somewhat arbitrary categorization of doses of jogging.
This categorization resulted in a smaller sample size
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421and lower statistical power for the higher doses of
jogging, where no mortality beneﬁts were found. For
example, there were only 47 joggers (4%) with the
highest jogging time (>4 h per week) and 80 joggers
(9%) with the highest frequency (>3 times per week),
with only 1 death and 5 deaths in the respective cate-
gories. However, the adjusted hazard ratios were 0.60
(95% conﬁdence interval: 0.08 to 4.36) and 0.71 (95%
conﬁdence interval: 0.29 to 1.75) in each respective
category, suggesting that signiﬁcantmortality beneﬁts
would be possible even with these highest doses of
jogging if these groups had sufﬁcient sample sizes. In
our recent study of running and mortality in 55,137
participants (13,016 runners) with 3,413 deaths (2), we
used 5 quintiles so there would be an equal number of
participants across different doses of running. We still
found signiﬁcantly lower risks of mortality even in the
highest quintiles of running time ($176 min per week)
and frequency ($6 times per week) compared with
nonrunners. Therefore, it is possible that running even
at high dosesmay providemortality beneﬁts compared
with nonrunners.
Third, Schnohr et al. (1) did not fully take into ac-
count participation in other types of PA. Jogging is
one type of PA, and it is possible that nonjoggers and
joggers unequally participated in other types of PA.FIGURE 1 Death Rates for Major Causes of Death by Weekly Runnin
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Participants were classiﬁed into 5 groups: nonrunners and 4 quartiles of w
age, sex, and examination year. CHD ¼ coronary heart disease; CVD ¼ cHowever, we found mortality beneﬁts of running
after adjusting for the total amount of other PA (2).
We also found similar mortality beneﬁts of running
even after excluding subjects who reported partici-
pating in other PA besides running. Thus, it is likely
that running provides mortality beneﬁts independent
of participating in other types of PA.
Fourth, Schnohr et al. (1) focused on the effects of
jogging only on all-cause mortality because of the
limited sample size. However, several studies have
reported the potential adverse effects of excessive
aerobic exercise speciﬁcally on cardiovascular dis-
eases and mortality. In a recent long-distance (90-km)
cross-country ski marathon study of 52,755 partici-
pants (3), the investigators found a higher risk of
developing arrhythmias in those who had completed
more races. In marathon runners, frequent marathon
running and its required training also appeared to be
correlated with myocardial damage (4,5). In addition,
recent evidence suggests that high doses of PA (>30
miles per week of running and >46 miles per week of
walking) in subjects with established coronary heart
disease (CHD) were associated with loss of cardio-
vascular mortality beneﬁt (6,7). In contrast, there are
other studies showing opposite results, with lower
risks of CHD with higher doses of running (8,9). In ourg Time
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422additional assessments of the effects of running and
mortality, we also evaluated cause-speciﬁc mortality
(Figure 1). It appears that mortality from all causes
and cancer was lower in runners compared with
nonrunners regardless of dose, although there was
a slight nonsigniﬁcant trend for less beneﬁt with
higher doses of running compared with lower doses
of running for all-cause mortality. On the other hand,
CHD mortality appeared to be relatively higher in
those with higher doses of running compared with
lower doses, with a reverse J-shaped association.
Thus, further studies are needed to better evaluate
this controversial issue. Ideally, these studies will be
well-controlled interventions, because we certainly
agree that the goal is not to unnecessarily frighten
people who wish to participate in more strenuous
exercise (10).
In summary, the study by Schnohr et al. (1) adds to
the current body of evidence on the dose-response
relationship between running and mortality. Howev-
er, further exploration is clearly warranted regarding
whether there is an optimal amount of running for
mortality beneﬁts, especially for cardiovascular andCHD mortality. In addition, because self-reported
doses of running may induce measurement error
and bias, it would be preferable to use an objective
assessment of doses of running in future studies.
The authors showed that even <1 h per week of
jogging, below the current minimum guidelines of
vigorous-intensity aerobic PA ($75 min per week),
may be sufﬁcient for mortality beneﬁts, consistent
with other large studies (2,9,11). Therefore, as a better
option for time efﬁciency, we should emphasize that
even small amounts of running (<1 h per week) can
provide signiﬁcant mortality beneﬁts for most healthy
but sedentary people. The general consensus of the
data certainly suggests that “more is not better!”
regarding running and mortality. However, we still
need more data to truly determine “is more actually
worse?” regarding exercise dose and prognosis.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Duck-chul Lee, Department of Kinesiology, College
of Human Sciences, Iowa State University, 251 For-
ker Building, Ames, Iowa 50011. E-mail: dclee@
iastate.edu.RE F E RENCE S1. Schnohr P, O’Keefe JH, Marott JL, Lange P,
Jensen GB. Dose of jogging and long-term mor-
tality: the Copenhagen City Heart Study. J Am Coll
Cardiol 2015;65:411–9.
2. Lee DC, Pate RR, Lavie CJ, Sui X, Church TS,
Blair SN. Leisure-time running reduces all-cause
and cardiovascular mortality risk. J Am Coll Car-
diol 2014;64:472–81.
3. Andersen K, Farahmand B, Ahlbom A, et al. Risk
of arrhythmias in 52 755 long-distance cross-
country skiers: a cohort study. Eur Heart J 2013;
34:3624–31.
4. Mohlenkamp S, Lehmann N, Breuckmann F,
et al. Running: the risk of coronary events: prev-
alence and prognostic relevance of coronary
atherosclerosis in marathon runners. Eur Heart J
2008;29:1903–10.5. Neilan TG, Januzzi JL, Lee-Lewandrowski E,
et al. Myocardial injury and ventricular dysfunction
related to training levels among nonelite partici-
pants in the Boston Marathon. Circulation 2006;
114:2325–33.
6. Williams PT, Thompson PD. Increased cardio-
vascular disease mortality associated with exces-
sive exercise in heart attack survivors. Mayo Clin
Proc 2014;89:1187–94.
7. O’Keefe JH, Franklin B, Lavie CJ. Exercising
for health and longevity vs peak performance:
different regimens for different goals. Mayo Clin
Proc 2014;89:1171–5.
8. Williams PT. Reductions in incident coronary
heart disease risk above guideline physical
activity levels in men. Atherosclerosis 2010;209:
524–7.9. Chomistek AK, Cook NR, Flint AJ, Rimm EB.
Vigorous-intensity leisure-time physical activity
and risk of major chronic disease in men. Med Sci
Sports Exerc 2012;44:1898–905.
10. Levine BD. Can intensive exercise harm the
heart? The beneﬁts of competitive endurance
training for cardiovascular structure and function.
Circulation 2014;130:987–91.
11. Wen CP, Wai JP, Tsai MK, et al. Minimum
amount of physical activity for reduced mortality
and extended life expectancy: a prospective
cohort study. Lancet 2011;378:1244–53.KEY WORDS cardiovascular disease,
dose response, mortality, physical activity,
running
